Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter L Greenberg

Showing results (21-30 of 93) with videos related to

Pageof 10
Sort By:
American Journal of Clinical Pathology|November 13, 2014
Mesenchymal stromal cell density is increased in higher grade myelodysplastic syndromes and independently predicts survivalRyan C Johnson, Jason H Kurzer, Peter L Greenberg, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|June 20, 2012
Distinctive contact between CD34+ hematopoietic progenitors and CXCL12+ CD271+ mesenchymal stromal cells in benign and myelodysplastic bone marrowEugenia Flores-Figueroa, Sushama Varma, Kelli Montgomery, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 18, 2008
The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network GuidelinesPeter L Greenberg, Leon E Cosler, Salvatore A Ferro, et al.
Leukemia Research|June 30, 2022
Epidemiologic evaluation of clinical outcomes in ethnic minorities with myelodysplastic syndromesAlfonso Molina, Lan Xiao, Quinn T Ostrom, et al.
Blood|October 6, 2009
Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progressionKunju Sridhar, Douglas T Ross, Robert Tibshirani, et al.
American Journal of Hematology|November 14, 2008
A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromesJason Gotlib, Philip Lavori, Sylvia Quesada, et al.
Leukemia Research|July 20, 2025
Molecular taxonomy of MDS/CMML patients influences responses to hypomethylating agents and clinical outcomesAlfonso Molina, Vishesh Khanna, Alexandria Jensen, et al.
Blood|October 17, 2012
Reduced rRNA expression and increased rDNA promoter methylation in CD34+ cells of patients with myelodysplastic syndromesAparna Raval, Kunju J Sridhar, Shripa Patel, et al.
Leukemia Research|July 10, 2010
Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromesPeter L Greenberg, Charles A Koller, Z Ioav Cabantchik, et al.
Cytometry. Part B, Clinical Cytometry|January 10, 2020
Profiling myelodysplastic syndromes by mass cytometry demonstrates abnormal progenitor cell phenotype and differentiationGregory K Behbehani, Rachel Finck, Nikolay Samusik, et al.
Pageof 10

Showing results (21-30 of 93) with videos related to

Sort By:
Pageof 10
American Journal of Clinical Pathology|November 13, 2014
Mesenchymal stromal cell density is increased in higher grade myelodysplastic syndromes and independently predicts survivalRyan C Johnson, Jason H Kurzer, Peter L Greenberg, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|June 20, 2012
Distinctive contact between CD34+ hematopoietic progenitors and CXCL12+ CD271+ mesenchymal stromal cells in benign and myelodysplastic bone marrowEugenia Flores-Figueroa, Sushama Varma, Kelli Montgomery, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 18, 2008
The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network GuidelinesPeter L Greenberg, Leon E Cosler, Salvatore A Ferro, et al.
Leukemia Research|June 30, 2022
Epidemiologic evaluation of clinical outcomes in ethnic minorities with myelodysplastic syndromesAlfonso Molina, Lan Xiao, Quinn T Ostrom, et al.
Blood|October 6, 2009
Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progressionKunju Sridhar, Douglas T Ross, Robert Tibshirani, et al.
American Journal of Hematology|November 14, 2008
A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromesJason Gotlib, Philip Lavori, Sylvia Quesada, et al.
Leukemia Research|July 20, 2025
Molecular taxonomy of MDS/CMML patients influences responses to hypomethylating agents and clinical outcomesAlfonso Molina, Vishesh Khanna, Alexandria Jensen, et al.
Blood|October 17, 2012
Reduced rRNA expression and increased rDNA promoter methylation in CD34+ cells of patients with myelodysplastic syndromesAparna Raval, Kunju J Sridhar, Shripa Patel, et al.
Leukemia Research|July 10, 2010
Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromesPeter L Greenberg, Charles A Koller, Z Ioav Cabantchik, et al.
Cytometry. Part B, Clinical Cytometry|January 10, 2020
Profiling myelodysplastic syndromes by mass cytometry demonstrates abnormal progenitor cell phenotype and differentiationGregory K Behbehani, Rachel Finck, Nikolay Samusik, et al.
Pageof 10